Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) closed at $3.66 in the last session, down -5.43% from day before closing price of $3.87. In other words, the price has decreased by -$5.43 from its previous closing price. On the day, 0.52 million shares were traded. AMLX stock price reached its highest trading level at $3.85 during the session, while it also had its lowest trading level at $3.5501.
Ratios:
We take a closer look at AMLX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.67 and its Current Ratio is at 6.67. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on November 18, 2024, Upgraded its rating to Outperform and sets its target price to $11 from $3 previously.
On October 23, 2024, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4.20 to $10.
Mizuho Downgraded its Buy to Neutral on March 18, 2024, whereas the target price for the stock was revised from $32 to $4.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 20 ’25 when Zeiher Bernhardt G bought 10,000 shares for $3.70 per share. The transaction valued at 37,005 led to the insider holds 10,000 shares of the business.
Klee Justin B. sold 4,595 shares of AMLX for $14,483 on Mar 03 ’25. The Co-Chief Executive Officer now owns 3,196,648 shares after completing the transaction at $3.15 per share. On Mar 03 ’25, another insider, Cohen Joshua B, who serves as the Co-Chief Executive Officer of the company, sold 4,595 shares for $3.17 each. As a result, the insider received 14,549 and left with 3,196,652 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMLX now has a Market Capitalization of 324285152 and an Enterprise Value of 149765040. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.71 while its Price-to-Book (P/B) ratio in mrq is 1.52. Its current Enterprise Value per Revenue stands at 1.714 whereas that against EBITDA is -0.515.
Stock Price History:
The Beta on a monthly basis for AMLX is -0.59, which has changed by 0.3505535 over the last 52 weeks, in comparison to a change of 0.06429911 over the same period for the S&P500. Over the past 52 weeks, AMLX has reached a high of $7.27, while it has fallen to a 52-week low of $1.58. The 50-Day Moving Average of the stock is 3.27%, while the 200-Day Moving Average is calculated to be 8.00%.
Shares Statistics:
According to the various share statistics, AMLX traded on average about 825.47K shares per day over the past 3-months and 597650 shares per day over the past 10 days. A total of 68.63M shares are outstanding, with a floating share count of 63.79M. Insiders hold about 28.01% of the company’s shares, while institutions hold 56.45% stake in the company. Shares short for AMLX as of 1741910400 were 3747333 with a Short Ratio of 4.54, compared to 1739491200 on 3378306. Therefore, it implies a Short% of Shares Outstanding of 3747333 and a Short% of Float of 4.5500003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
